Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. Issue 1 (9th June 2020)

• Record Type: Journal Article
• Authors: Wada, Eri; Onoue, Takeshi; Kobayashi, Tomoko; Handa, Tomoko; Hayase, Ayaka; Ito, Masaaki; Furukawa, Mariko; Okuji, Takayuki; Okada, Norio; Iwama, Shintaro; Sugiyama, Mariko; Tsunekawa, Taku; Takagi, Hiroshi; Hagiwara, Daisuke; Ito, Yoshihiro; Suga, Hidetaka; Banno, Ryoichi; Kuwatsuka, Yachiyo; Ando, Masahiko; Goto, Motomitsu; Arima, Hiroshi
• Is Part Of: BMJ open diabetes research and care. Volume 8:Issue 1(2020)
• Publication Date: 2020-06-09
• Subjects: clinical trial(s) -- education and behavioral interventions -- glucose monitoring -- HbA1c; Diabetes -- Periodicals; 616.462005
• DOI: 10.1136/bmjdrc-2019-001115
• Languages: English
• ISSNs: 2052-4897

Abstract

Abstract : Introduction: The present study aimed to evaluate the effects of flash glucose monitoring (FGM) and conventional self-monitoring of blood glucose (SMBG) on glycemic control in patients with non-insulin-treated type 2 diabetes. Research design and methods: In this 24-week, multicenter, open-label, randomized (1:1), parallel-group study, patients with non-insulin-treated type 2 diabetes at five hospitals in Japan were randomly assigned to the FGM (n=49) or SMBG (n=51) groups and were provided each device for 12 weeks. The primary outcome was change in glycated hemoglobin (HbA1c) level, and was compared using analysis of covariance model that included baseline values and group as covariates. Results: Forty-eight participants in the FGM group and 45 in the SMBG group completed the study. The mean HbA1c levels were 7.83% (62.1 mmol/mol) in the FGM group and 7.84% (62.2 mmol/mol) in the SMBG group at baseline, and the values were reduced in both FGM (−0.43% (−4.7 mmol/mol), p<0.001) and SMBG groups (−0.30% (−3.3 mmol/mol), p=0.001) at 12 weeks. On the other hand, HbA1c was significantly decreased from baseline values in the FGM group, but not in the SMBG group at 24 weeks (FGM: −0.46% (−5.0 mmol/mol), p<0.001; SMBG: −0.17% (−1.8 mmol/mol), p=0.124); a significant between-group difference was also observed (difference −0.29% (−3.2 mmol/mol), p=0.022). Diabetes Treatment Satisfaction Questionnaire score was significantly improved, and the mean glucose levels, SD of glucose, mean amplitude of glycemic excursions and time in hyperglycemia were significantly decreased in the FGM group compared with the SMBG group. Conclusions: Glycemic control was better with FGM than with SMBG after cessation of glucose monitoring in patients with non-insulin-treated type 2 diabetes. Trial registration number: UMIN000026452, jRCTs041180082.